Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2016 16:01 ET | Source: Achaogen Inc.

Achaogen Reports Third Quarter 2016 Financial Results and Announces Acceleration of Expected Timeline for Reporting Top-Line Results from Plazomicin Program

-- Completed Enrollment in Phase 3 Plazomicin Clinical Trials; Expect Results from EPIC and CARE Trials by End of 2016 -- -- Planning Plazomicin NDA Submission in the Second Half of 2017 -- --...
November 01, 2016 08:05 ET | Source: Achaogen Inc.

Achaogen to Host Conference Call and Webcast of Third Quarter 2016 Financial Results on November 7, 2016

SOUTH SAN FRANCISCO, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
October 24, 2016 16:05 ET | Source: Achaogen Inc.

Achaogen to Present First Plazomicin CARE Trial Data in Patients with Carbapenem-Resistant Enterobacteriaceae (CRE) infections at IDWeek 2016

-- CARE trial clinical data highlight the contribution of therapeutic drug management in guiding targeted dosing of plazomicin in critically ill patients with antibiotic resistant...
September 27, 2016 08:00 ET | Source: Achaogen Inc.

Achaogen Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
September 01, 2016 08:00 ET | Source: Achaogen Inc.

Achaogen Completes Patient Enrollment in Phase 3 EPIC Clinical Trial of Plazomicin

SOUTH SAN FRANCISCO, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
August 22, 2016 08:00 ET | Source: Achaogen Inc.

Achaogen Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Aug. 22, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
August 10, 2016 08:00 ET | Source: Achaogen Inc.

Achaogen to Present at the Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
August 08, 2016 16:01 ET | Source: Achaogen Inc.

Achaogen Reports Second Quarter 2016 Financial Results and Provides Corporate Update

-- Enrollment in Phase 3 EPIC registration clinical trial of plazomicin maintained momentum; top-line results from EPIC expected in the first quarter of 2017 ---- Secured $55 million in additional...
July 15, 2016 08:00 ET | Source: Achaogen Inc.

Achaogen to Host Key Opinion Leader Meeting on Multi-Drug Resistant Infections on July 19, 2016 in New York

SOUTH SAN FRANCISCO, Calif., July 15, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...
July 06, 2016 08:00 ET | Source: Achaogen Inc.

Achaogen Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a clinical-stage biopharmaceutical company developing novel antibacterials addressing multi-drug...